The US Food and Drug Administration approved the first-ever vaccine to treat cancer on 29 April. After a three-year battle with the regulatory agency and three phase 3 trials, the treatment—called Provenge, by Seattle-based Dendreon—extended median survival time in men with advanced prostate cancer by more than four months. (Click here to continue reading)

Image by Zaldylmg via Flickr Creative Commons